RedHill Biopharma RDHL Ratios (2012-2025)

NASDAQ RDHL
$0.69 +0.04 (+5.31%)
As of: Sep 9, 2026 · 3:59 PM EDT
Reported Financials

RedHill Biopharma Quarterly Ratios

Periods 51 quarters
Latest Dec 2025

RedHill Biopharma ratios data for the quarter ended Dec 2025. These financial ratios cover 51 quarters of results from Mar 2012 through Dec 2025, standardized by Business Quant from the company’s SEC filings.

Ratios Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Dec2023 Jun2024 Dec2024 Jun2025 Dec2025
Profitability
Gross Margin
50.44%-62.41%32.11%50.64%50.37%50.17%50.75%57.29%12.40%51.98%50.97%46.15%32.82%55.21%55.12%
EBT Margin
744.47%1,557.48%42.84%49.10%70.29%65.33%96.04%62.05%-658.08%97.15%36.01%-122.41%-543.22%-220.03%3,280.68%
EBIT Margin
739.87%1,611.36%59.81%69.04%91.83%88.22%115.74%80.51%-641.43%126.90%49.92%40.50%-591.81%-808.00%2,992.87%
EBITDA Margin
739.87%1,611.36%59.81%69.04%91.83%88.22%115.74%80.51%-641.43%126.90%49.92%40.50%-591.81%-808.00%2,992.87%
Operating Margin
739.87%1,611.36%59.81%69.04%91.83%88.22%115.74%80.51%-641.43%126.90%49.92%40.50%-591.81%-808.00%2,992.87%
Net Margin
744.47%1,557.48%42.84%49.10%70.29%65.33%96.04%62.05%-658.08%97.15%36.01%-122.41%-543.22%-220.03%3,280.68%
FCF Margin
-870.19%-983.14%-71.82%-43.00%-58.97%-59.19%-87.88%-87.94%-67.31%-31.61%-89.49%-34.22%-18.92%-199.67%-589.59%
Efficiency
Inventory AverageInventory Avg.
0.00B0.00B0.00B0.00B0.01B0.01B0.01B0.01B0.01B0.01B0.01B0.01B0.01B0.01B0.01B0.00B0.00B0.00B0.00B
Assets AverageAssets Avg.
0.06B0.11B0.15B0.17B0.17B0.20B0.21B0.20B0.18B0.17B0.17B0.16B0.16B0.11B0.05B0.03B0.02B0.02B0.02B0.02B
Invested CapitalInvested Cap.
0.12B0.11B0.11B0.10B0.14B0.11B0.10B0.09B0.08B0.07B0.07B0.07B
Asset Utilization RatioAsset Util.
0.110.050.160.270.370.420.400.440.470.450.450.440.390.480.76
Leverage & Solvency
Interest Coverage RatioInterest Cover
62.9147.933.423.434.243.825.864.34-38.414.252.170.22-30.53-69.0727.91
Debt Ratio
0.540.480.480.450.370.410.450.460.520.510.720.73
Times Interest Earned
62.9147.933.423.434.243.825.864.34-38.414.252.170.22-30.53-69.0727.91
Valuation
Price to EarningsP/E
0.00B0.00B0.00B0.00B0.00B0.00B0.00B0.00B-935.830.00B0.00B-0.00B-124.71-799.6431.53
Price to SalesP/S
0.00B0.00B0.00B0.00B0.00B0.00B0.00B0.00B0.00B0.00B0.00B0.00B677.460.00B0.00B
Price to BookP/B
0.00B0.00B0.00B0.00B0.00B0.00B0.00B0.00B0.00B-0.00B-0.00B-574.61-179.14535.260.00B0.00B-343.61-113.943.56
Enterprise Value
214.03B159.69B236.22B360.43B310.21B281.00B264.10B175.81B135.88B132.73B45.81B26.43B8.65B6.31B1.84B9.45B2.39B1.60B0.49B0.01B
EV to EBIT
0.00B0.00B0.00B0.00B0.00B0.00B0.00B0.00B-959.800.00B0.00B0.00B-114.21-217.1534.19
EV to EBITDA
0.00B0.00B0.00B0.00B0.00B0.00B0.00B0.00B-959.800.00B0.00B0.00B-114.21-217.1534.19
Market Capitalization
214.09B159.77B236.31B360.45B310.26B281.07B264.18B175.86B135.93B132.76B45.84B26.45B8.67B6.33B1.86B9.46B2.40B1.61B0.50B0.02B
Price to FCFP/FCF
-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-881.20-175.46
EV to FCF
-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-878.74-173.56
EV to CFO
-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B-878.74-173.56
Return Ratios
Return on Sales [ROS]ROS
739.87%1,611.36%59.81%69.04%91.83%88.22%115.74%80.51%-641.43%126.90%49.92%40.50%-591.81%-808.00%2,992.87%
Return on Capital Employed [ROCE]ROCE
92.79%42.94%62.82%58.17%-79.32%-9,001.37%108.68%-234.47%
Return on Assets [ROA]ROA
77.13%47.79%30.40%28.34%29.07%23.86%28.06%32.09%-53.19%-56.54%-67.16%-90.66%-45.35%-84.81%-85.23%